Merck - 63 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1962 adjusted for splits and dividends. The latest closing stock price for Merck as of June 06, 2025 is 78.97.
  • The all-time high Merck stock closing price was 129.91 on June 24, 2024.
  • The Merck 52-week high stock price is 134.63, which is 70.5% above the current share price.
  • The Merck 52-week low stock price is 73.31, which is 7.2% below the current share price.
  • The average Merck stock price for the last 52 weeks is 101.81.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2025 86.8366 98.3206 100.1550 73.4700 78.9700 -19.93%
2024 115.4299 109.2870 129.9050 94.7268 98.6279 -6.26%
2023 102.8071 104.3410 111.9110 95.9880 105.2140 1.01%
2022 82.9310 69.9198 105.2610 66.8636 104.1620 49.42%
2021 67.7375 67.8053 81.5799 60.4435 69.7106 1.75%
2020 66.5459 74.7144 74.7144 54.3458 68.5088 -7.21%
2019 65.7496 59.7349 74.4709 57.6249 73.8295 22.27%
2018 49.9107 43.1074 62.2621 41.1752 60.3828 39.95%
2017 46.8813 44.7500 50.3015 41.1322 43.1457 -1.49%
2016 42.0542 37.8228 47.9607 35.0193 43.7977 15.05%
2015 40.0256 39.8878 43.9609 34.5980 38.0679 -3.89%
2014 39.2397 33.4951 42.8353 33.4951 39.6088 16.93%
2013 30.7793 26.9706 33.8741 26.6509 33.8741 26.82%
2012 26.3458 23.9848 30.9925 23.3648 26.7096 13.13%
2011 20.8258 21.5496 23.7342 18.2279 23.6090 9.56%
2010 21.0361 21.2099 23.5137 18.4264 21.5496 2.91%
2009 16.5373 16.8544 21.7772 11.6032 20.9405 26.70%
2008 19.6050 29.8499 31.5044 12.6270 16.5281 -45.33%
2007 25.9677 22.2249 31.6189 21.6797 30.2349 37.35%
2006 18.9619 15.8848 23.1354 15.8848 22.0129 42.67%
2005 14.4626 14.4240 16.3102 12.3795 15.4289 4.04%
2004 18.9339 20.9092 21.8305 11.8344 14.8300 -27.77%
2003 22.4345 23.7907 26.1772 17.8859 20.5315 -11.20%
2002 21.7527 23.7863 25.7671 15.7323 23.1208 -1.21%
2001 28.0426 36.3038 36.3038 22.7554 23.4042 -35.96%
2000 28.5421 25.9493 36.9869 20.7950 36.5478 41.76%
1999 27.8651 28.2927 32.7494 23.1966 25.7814 -7.49%
1998 24.1394 20.0247 29.9813 19.1409 27.8676 41.30%
1997 17.3994 14.5851 19.9665 14.5851 19.7223 35.65%
1996 12.2937 11.4857 15.3079 10.2402 14.5395 23.94%
1995 8.7363 6.6650 11.9550 6.3601 11.7315 76.59%
1994 5.6943 5.9316 6.8611 4.8168 6.6432 14.85%
1993 5.8084 7.1647 7.1647 4.7559 5.7844 -18.34%
1992 7.8427 8.8821 9.0156 6.6790 7.0831 -20.31%
1991 6.3408 4.6862 8.8888 4.3066 8.8888 88.89%
1990 4.0827 4.0138 4.7058 3.4490 4.7058 18.94%
1989 3.5535 2.8527 4.0606 2.8527 3.9563 37.49%
1988 2.6926 2.6658 2.9449 2.3597 2.8776 11.95%
1987 2.7033 2.0116 3.5108 2.0116 2.5705 29.97%
1986 1.5114 1.0790 2.0675 1.0585 1.9777 84.62%
1985 0.8461 0.7070 1.0712 0.6861 1.0712 50.09%
1984 0.6600 0.6627 0.7170 0.5947 0.7137 7.70%
1983 0.6563 0.5969 0.7586 0.5827 0.6627 10.21%
1982 0.5358 0.5855 0.6236 0.4483 0.6013 3.62%
1981 0.5854 0.5713 0.6899 0.5196 0.5803 3.07%
1980 0.4752 0.4546 0.5630 0.3811 0.5630 21.26%
1979 0.4270 0.4235 0.4731 0.3965 0.4643 10.05%
1978 0.3537 0.3246 0.4313 0.2937 0.4219 25.57%
1977 0.3348 0.3944 0.3944 0.2985 0.3360 -16.21%
1976 0.4162 0.4013 0.4704 0.3708 0.4010 0.45%
1975 0.4251 0.3806 0.4882 0.3325 0.3992 6.25%
1974 0.4040 0.4483 0.4818 0.2773 0.3757 -16.59%
1973 0.4941 0.4975 0.5543 0.4318 0.4504 -8.08%
1972 0.4177 0.3404 0.4914 0.3404 0.4900 45.40%
1971 0.2852 0.2529 0.3554 0.2529 0.3370 27.85%
1970 0.2443 0.2908 0.2934 0.1949 0.2636 -10.77%
1969 0.2468 0.2362 0.2980 0.2163 0.2954 25.54%
1968 0.2226 0.2117 0.2483 0.1928 0.2353 6.66%
1967 0.2169 0.1967 0.2454 0.1947 0.2206 9.97%
1966 0.1931 0.1876 0.2111 0.1702 0.2006 8.84%
1965 0.1531 0.1268 0.1947 0.1268 0.1843 42.10%
1964 0.1072 0.0962 0.1297 0.0902 0.1297 35.95%
1963 0.0814 0.0679 0.0955 0.0679 0.0954 41.12%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $198.296B $64.168B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $729.643B 55.95
Johnson & Johnson (JNJ) United States $373.014B 15.43
AbbVie (ABBV) United States $335.316B 18.48
Roche Holding AG (RHHBY) Switzerland $260.602B 0.00
Novartis AG (NVS) Switzerland $249.308B 14.24
Pfizer (PFE) United States $132.753B 7.27
Sanofi (SNY) France $123.776B 12.19
Bayer (BAYRY) Germany $29.826B 6.07
Innoviva (INVA) United States $1.355B 14.20
Novo Nordisk (NVO) Denmark $0.000B 22.08